✦ LIBER ✦

A bioluminescent enzyme immunoassay for prostaglandin E2 using Cypridina luciferase

✍ Scribed by Chun Wu; Saki Irie; Shozo Yamamoto; Yoshihiro Ohmiya

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 150 KB
Volume: 24
Category: Article
ISSN: 1522-7235
DOI: 10.1002/bio.1086

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Prostaglandin E~2~ is one of the major cyclooxygenase metabolites of arachidonic acid. We developed a competitive immunosorbent assay for prostaglandin E~2~ utilizing a bioluminescent enzyme Cypridina luciferase. The prostaglandin E~2~ amount could be quantified over the concentration ranging from 7.8 to 500 pg/mL. The amount of unlabeled prostaglandin E~2~ required to displace 50% of the maximal binding of Cypridina luciferase‐labeled prostaglandin E~2~ (B/B~0~) was approximately 35 pg/mL. The results show a great potential of Cypridina luciferase as a new labeling enzyme for enzyme‐linked immunosorbent assay. Copyright © 2009 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Practical application of bioluminescence

Practical application of bioluminescence enzyme immunoassay using enhancer for firefly luciferin–luciferase bioluminescence

✍ Takayuki Minekawa; Hiroshi Ohkuma; Katsushi Abe; Hiroaki Maekawa; Hidetoshi Arak 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 410 KB

Development of ultra-high sensitivity bi

Development of ultra-high sensitivity bioluminescent enzyme immunoassay for prostate-specific antigen (PSA) using firefly luciferase

✍ Yoshiaki Seto; Toshihiko Iba; Katsushi Abe 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 1 views

Development of ultra-high sensitivity bi

Development of ultra-high sensitivity bioluminescent enzyme immunoassay for hepatitis B virus surface antigen using firefly luciferase

✍ Takayuki Minekawa; Hiroshi Ohkuma; Katsushi Abe; Hiroaki Maekawa; Hidetoshi Arak 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 447 KB 👁 1 views

## Abstract Hepatitis B virus (HBV) infection continues to be a global public health concern. Efficient diagnosis of HBV surface antigen (HBsAg) is useful for identification of infection, treatment and prevention of transfusion‐transmitted viral infections. Seronegative window reduction afforded by